Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach [0.03%]
基于表型的二型糖尿病个性化治疗算法
Antonio Ceriello,Marco Gallo,Riccardo Candido et al.
Antonio Ceriello et al.
Type 2 diabetes is a progressive disease with a complex and multifactorial pathophysiology. Patients with type 2 diabetes show a variety of clinical features, including different "phenotypes" of hyperglycemia (eg, fasting/preprandial or pos...
Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders [0.03%]
CYP2D6*10多态性对日本抑郁症患者帕罗西汀非线性药动学参数估计的影响
Junji Saruwatari,Hiroo Nakashima,Shoko Tsuchimine et al.
Junji Saruwatari et al.
It has been suggested that the reduced function allele with reduced cytochrome P450 (CYP) 2D6 activity, CYP2D6*10, is associated with the interindividual differences in the plasma paroxetine concentrations, but there is no data presently av...
Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients [0.03%]
EPHX1和CYP3A4多态性对癫痫患者卡马西平代谢的影响
Antonietta Caruso,Chiara Bellia,Alessia Pivetti et al.
Antonietta Caruso et al.
Background: The aim of this study was to investigate the effect of two genetic polymorphisms in the coding regions (exon 3 and exon 4) of the EPHX1 gene, ie, 337T>C and 416A>G, respectively, on the metabolism of carbamaze...
Elena Verzoni,Paolo Grassi,Isabella Testa et al.
Elena Verzoni et al.
Antiangiogenesis options have evolved rapidly in the last few years, with an increasing number of agents currently approved by the US Food and Drug Administration and European Medicines Agency. Angiogenesis inhibitors have been shown to be ...
Precision medicine and personalized breast cancer: combination pertuzumab therapy [0.03%]
精准医学和个性化的乳腺癌治疗：帕妥珠单抗联合疗法
Kerry Reynolds,Sasmit Sarangi,Aditya Bardia et al.
Kerry Reynolds et al.
Trastuzumab (Herceptin), a monoclonal antibody directed against the human epidermal growth-factor receptor 2 (HER2), is the poster child for antibody-based targeted therapy in breast cancer. Pertuzumab, another humanized monoclonal antibody...
Carlos Murga-Zamalloa,Megan S Lim
Carlos Murga-Zamalloa
Receptor tyrosine kinases have emerged as promising therapeutic targets for a diverse set of tumors. Overactivation of the tyrosine kinase anaplastic lymphoma kinase (ALK) has been reported in several types of malignancies such as anaplasti...
Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma [0.03%]
Brentuximab Vedotin在复发或难治性霍奇金淋巴瘤治疗中的作用
Tanya Siddiqi,Sandra H Thomas,Robert Chen
Tanya Siddiqi
Brentuximab vedotin (BV) is an antibody-drug conjugate that targets CD30-positive malignancies via an anti-CD30 monoclonal antibody linked to monomethyl auristatin E, a microtubule-disrupting agent, by a protease-cleavable linker. BV has re...
Glioblastoma extracellular vesicles: reservoirs of potential biomarkers [0.03%]
胶质母细胞瘤外泌体：潜在生物标志物的宝库
Jasmina S Redzic,Timothy H Ung,Michael W Graner
Jasmina S Redzic
Glioblastoma multiforme (GBM) is the most frequent and most devastating of the primary central nervous system tumors, with few patients living beyond 2 years postdiagnosis. The damage caused by the disease and our treatments for the patient...
Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics [0.03%]
ABCG2/BCRP介导的肿瘤耐药：分子肿瘤治疗的基础和临床研究展望
Kohji Noguchi,Kazuhiro Katayama,Yoshikazu Sugimoto
Kohji Noguchi
Adenine triphosphate (ATP)-binding cassette (ABC) transporter proteins, such as ABCB1/P-glycoprotein (P-gp) and ABCG2/breast cancer resistance protein (BCRP), transport various structurally unrelated compounds out of cells. ABCG2/BCRP is re...
Kristin Schroeder,Sri Gururangan
Kristin Schroeder
Medulloblastoma is the commonest malignant brain tumor in children. Treatment with surgery, irradiation, and chemotherapy has improved outcomes in recent years, but patients are frequently left with devastating neurocognitive and other sequ...